{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:29:38Z","timestamp":1791523778507,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent novel, selective and reversible chemical probes that simultaneously inhibit the G9a and DNMTs methyltransferase activity.\n                    <jats:italic>In vitro<\/jats:italic>\n                    treatment of haematological neoplasia (acute myeloid leukaemia-AML, acute lymphoblastic leukaemia-ALL and diffuse large B-cell lymphoma-DLBCL) with the lead compound CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death. CM-272 significantly prolongs survival of AML, ALL and DLBCL xenogeneic models. Our results represent the discovery of first-in-class dual inhibitors of G9a\/DNMTs and establish this chemical series as a promising therapeutic tool for unmet needs in haematological tumours.\n                  <\/jats:p>","DOI":"10.1038\/ncomms15424","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T06:20:27Z","timestamp":1495779627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies"],"prefix":"10.1038","volume":"8","author":[{"given":"Edurne","family":"San Jos\u00e9-En\u00e9riz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Rabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Vilas-Zornoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Sanchez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ugarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-0715","authenticated-orcid":false,"given":"Sergio","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Estella-Hermoso de Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I.","family":"Mart\u00edn-Subero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Ogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara M.","family":"Santiveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Campos-Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite Garcia Fernandez","family":"de Barrena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan Roberto","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Garc\u00eda-Barchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Lasarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias A","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Angel","family":"Martinez-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Oyarzabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"BFncomms15424_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature12751","volume":"502","author":"K Helin","year":"2013","unstructured":"Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480\u2013488 (2013).","journal-title":"Nature"},{"key":"BFncomms15424_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrd3674","volume":"11","author":"CH Arrowsmith","year":"2012","unstructured":"Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384\u2013400 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms15424_CR3","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane, A. A. & Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459\u20135468 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15424_CR4","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa, J. P. & Kantarjian, H. M. Targeting DNA methylation. Clin. Cancer Res. 15, 3938\u20133946 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms15424_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.01.002","volume":"150","author":"J McGrath","year":"2015","unstructured":"McGrath, J. & Trojer, P. Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1\u201322 (2015).","journal-title":"Pharmacol. Ther."},{"key":"BFncomms15424_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1476-4598-13-189","volume":"13","author":"KT Hua","year":"2014","unstructured":"Hua, K. T. et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol. Cancer 13, 189 (2014).","journal-title":"Mol. Cancer"},{"key":"BFncomms15424_CR7","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1158\/0008-5472.CAN-10-0833","volume":"70","author":"MW Chen","year":"2010","unstructured":"Chen, M. W. et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 70, 7830\u20137840 (2010).","journal-title":"Cancer Res."},{"key":"BFncomms15424_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/his.12456","volume":"66","author":"X Zhong","year":"2015","unstructured":"Zhong, X. et al. Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis. Histopathology 66, 192\u2013200 (2015).","journal-title":"Histopathology"},{"key":"BFncomms15424_CR9","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.18632\/oncotarget.2784","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget 6, 2917\u20132927 (2015).","journal-title":"Oncotarget"},{"key":"BFncomms15424_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1101\/gad.236794.113","volume":"28","author":"B Lehnertz","year":"2014","unstructured":"Lehnertz, B. et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28, 317\u2013327 (2014).","journal-title":"Genes Dev."},{"key":"BFncomms15424_CR11","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1101\/gad.1463706","volume":"20","author":"PO Esteve","year":"2006","unstructured":"Esteve, P. O. et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev. 20, 3089\u20133103 (2006).","journal-title":"Genes Dev."},{"key":"BFncomms15424_CR12","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/emboj.2008.192","volume":"27","author":"M Tachibana","year":"2008","unstructured":"Tachibana, M., Matsumura, Y., Fukuda, M., Kimura, H. & Shinkai, Y. G9a\/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J. 27, 2681\u20132690 (2008).","journal-title":"EMBO J."},{"key":"BFncomms15424_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/sj.onc.1209763","volume":"26","author":"RJ Wozniak","year":"2007","unstructured":"Wozniak, R. J., Klimecki, W. T., Lau, S. S., Feinstein, Y. & Futscher, B. W. 5-Aza-2\u2032-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26, 77\u201390 (2007).","journal-title":"Oncogene"},{"key":"BFncomms15424_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-8935-5-3","volume":"5","author":"S Sharma","year":"2012","unstructured":"Sharma, S. et al. Lysine methyltransferase G9a is not required for DNMT3A\/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells. Epigenetics Chromatin 5, 3 (2012).","journal-title":"Epigenetics Chromatin"},{"key":"BFncomms15424_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nsmb.1560","volume":"16","author":"Y Chang","year":"2009","unstructured":"Chang, Y. et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16, 312\u2013317 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFncomms15424_CR16","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1021\/jm901543m","volume":"52","author":"F Liu","year":"2009","unstructured":"Liu, F. et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52, 7950\u20137953 (2009).","journal-title":"J. Med. Chem."},{"key":"BFncomms15424_CR17","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1021\/jm100478y","volume":"53","author":"F Liu","year":"2010","unstructured":"Liu, F. et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 53, 5844\u20135857 (2010).","journal-title":"J. Med. Chem."},{"key":"BFncomms15424_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nchembio.599","volume":"7","author":"M Vedadi","year":"2011","unstructured":"Vedadi, M. et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7, 566\u2013574 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"BFncomms15424_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1126\/science.1214453","volume":"335","author":"J Song","year":"2012","unstructured":"Song, J., Teplova, M., Ishibe-Murakami, S. & Patel, D. J. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 335, 709\u2013712 (2012).","journal-title":"Science"},{"key":"BFncomms15424_CR20","unstructured":"Agirre, X. et al. Novel compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases. WO2015192981A1, 30 March (2015)."},{"key":"BFncomms15424_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ab.2012.01.019","volume":"423","author":"Y Lin","year":"2012","unstructured":"Lin, Y. et al. Detecting S-adenosyl-L-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay. Anal. Biochem. 423, 171\u2013177 (2012).","journal-title":"Anal. Biochem."},{"key":"BFncomms15424_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/1087057111421212","volume":"17","author":"JM Foulks","year":"2012","unstructured":"Foulks, J. M. et al. Epigenetic drug discovery: targeting DNA methyltransferases. J. Biomol. Screen. 17, 2\u201317 (2012).","journal-title":"J. Biomol. Screen."},{"key":"BFncomms15424_CR23","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1158\/0008-5472.CAN-08-4025","volume":"69","author":"X Agirre","year":"2009","unstructured":"Agirre, X. et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69, 4443\u20134453 (2009).","journal-title":"Cancer Res."},{"key":"BFncomms15424_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","volume":"109","author":"C Mestre-Escorihuela","year":"2007","unstructured":"Mestre-Escorihuela, C. et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109, 271\u2013280 (2007).","journal-title":"Blood"},{"key":"BFncomms15424_CR25","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1182\/blood-2008-04-152900","volume":"113","author":"JI Martin-Subero","year":"2009","unstructured":"Martin-Subero, J. I. et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113, 2488\u20132497 (2009).","journal-title":"Blood"},{"key":"BFncomms15424_CR26","doi-asserted-by":"publisher","first-page":"e12197","DOI":"10.1371\/journal.pone.0012197","volume":"5","author":"S Alvarez","year":"2010","unstructured":"Alvarez, S. et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE 5, e12197 (2010).","journal-title":"PLoS ONE"},{"key":"BFncomms15424_CR27","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/leu.2012.31","volume":"26","author":"A Vilas-Zornoza","year":"2012","unstructured":"Vilas-Zornoza, A. et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26, 1517\u20131526 (2012).","journal-title":"Leukemia"},{"key":"BFncomms15424_CR28","doi-asserted-by":"publisher","first-page":"12461","DOI":"10.1073\/pnas.1018941108","volume":"108","author":"E Beltran","year":"2011","unstructured":"Beltran, E. et al. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proc. Natl Acad. Sci. USA 108, 12461\u201312466 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15424_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/cncr.29085","volume":"121","author":"JP Issa","year":"2015","unstructured":"Issa, J. P. et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121, 556\u2013561 (2015).","journal-title":"Cancer"},{"key":"BFncomms15424_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.20112343","volume":"209","author":"TC Fang","year":"2012","unstructured":"Fang, T. C. et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J. Exp. Med. 209, 661\u2013669 (2012).","journal-title":"J. Exp. Med."},{"key":"BFncomms15424_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"BFncomms15424_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"BFncomms15424_CR33","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).","journal-title":"Oncoimmunology"},{"key":"BFncomms15424_CR34","doi-asserted-by":"crossref","first-page":"9740","DOI":"10.18632\/oncotarget.3149","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach. Oncotarget 6, 9740\u20139755 (2015).","journal-title":"Oncotarget"},{"key":"BFncomms15424_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/nsmb.1476","volume":"15","author":"S Epsztejn-Litman","year":"2008","unstructured":"Epsztejn-Litman, S. et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat. Struct. Mol. Biol. 15, 1176\u20131183 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFncomms15424_CR36","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/emboj.2010.140","volume":"29","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J. 29, 2538\u20132552 (2010).","journal-title":"EMBO J."},{"key":"BFncomms15424_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1021\/ml3003346","volume":"3","author":"SK Verma","year":"2012","unstructured":"Verma, S. K. et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3, 1091\u20131096 (2012).","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms15424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15424","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms15424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T19:45:07Z","timestamp":1671738307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms15424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,8,14]]}},"alternative-id":["BFncomms15424"],"URL":"https:\/\/doi.org\/10.1038\/ncomms15424","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,26]]},"assertion":[{"value":"22 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15424"}}